Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation

OBJECTIVES: Results from the SCOT (Scleroderma: Cyclophosphamide Or Transplantation) clinical trial demonstrated significant benefits of haematopoietic stem cell transplant (HSCT) versus cyclophosphamide (CTX) in patients with systemic sclerosis. The objective of this study was to test the hypothesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoglu, Burcu, Donato, Michele, Furst, Daniel E, Crofford, Leslie J, Goldmuntz, Ellen, Keyes-Elstein, Lynette, James, Judith, Macwana, Susan, Mayes, Maureen D, McSweeney, Peter, Nash, Richard A, Sullivan, Keith M, Welch, Beverly, Pinckney, Ashley, Mao, Rong, Chung, Lorinda, Khatri, Purvesh, Utz, Paul J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176357/
https://www.ncbi.nlm.nih.gov/pubmed/36653124
http://dx.doi.org/10.1136/ard-2021-221926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176357/
https://www.ncbi.nlm.nih.gov/pubmed/36653124
http://dx.doi.org/10.1136/ard-2021-221926

Ejemplares similares